What drove the 6.60% gain in NWRN.SW stock today?

The intraday gain to **CHF 21.00** came on **129,185** shares traded. Market moves likely reflect clinical or pipeline news and buying into the stock ahead of the 24 Mar 2026 earnings date.

What valuation metrics matter for NWRN.SW stock?

Key metrics are EPS **1.24**, trailing PE **16.94**, cash per share **2.16**, and price/book near **272.61**. PE is modest versus healthcare peers, but the high PB reflects intangible assets and R&D value.

How does Meyka AI view NWRN.SW stock?

Meyka AI rates NWRN.SW with a score out of 100 at **74.80** (Grade **B+**, Suggestion: **BUY**). The grade uses benchmark, sector, growth, metrics and consensus. Grades are informational and not investment advice.

What are realistic price targets for NWRN.SW stock?

Meyka AI's forecast model projects quarterly **CHF 30.94** and yearly **CHF 21.73**. Versus the current **CHF 21.00**, the one-year projection shows **3.48%** upside. Forecasts are projections, not guarantees.

CH Stocks

NWRN.SW stock up 6.60% to CHF 21.00 on SIX: drivers and what to watch next

ByDanny Kontos February 18, 2026February 18, 2026

NWRN.SW stock led Swiss movers on 17 Feb 2026, rising 6.60% to CHF 21.00 at market close on SIX. Volume reached 129,185 shares, tracking below the 50-day average of 164,857 but signaling renewed buyer interest after recent clinical updates. The move trims the gap to the 50-day average price of CHF 22.36 and follows improving 3-month performance of 32.58%. We examine fundamentals, technicals, Meyka AI grade and forecasts to explain the intraday gain and near-term outlook.